


## PHARMACEUTICAL 2020

## Urovant Sciences Ltd. Rank 315 of 362





## PHARMACEUTICAL 2020

## Urovant Sciences Ltd. Rank 315 of 362

The relative strengths and weaknesses of Urovant Sciences Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Urovant Sciences Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Urovant Sciences Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 369% points.

The company's Economic Capital Ratio, given in the ranking table, is -589%, being 286% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	98,510
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,817
Liabilities, Non-Current	13,534
Other Assets	688
Other Compr. Net Income	262
Other Expenses	304
Other Liabilities	0
Other Net Income	-259
Property and Equipment	923
Research and Development	92,198
Revenues	0
Selling, General and Administrative Expense	18,585

Output Variable	Value in 1000 USD
Assets	100,121
Liabilities	25,351
Expenses	111,087
Stockholders Equity	74,770
Net Income	-111,346
Comprehensive Net Income	-111,215
Economic Capital Ratio	-589%